Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Zodasiran by Arrowhead Pharmaceuticals for Mixed Dyslipidemia: Likelihood of Approval
Zodasiran is under clinical development by Arrowhead Pharmaceuticals and currently in Phase II for Mixed Dyslipidemia. According to GlobalData, Phase...
Zodasiran by Arrowhead Pharmaceuticals for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia): Likelihood of Approval
Zodasiran is under clinical development by Arrowhead Pharmaceuticals and currently in Phase II for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). According...
Risk adjusted net present value: What is the current valuation of Arrowhead Pharmaceuticals's Zodasiran?
Zodasiran is an antisense rnai oligonucleotide commercialized by Arrowhead Pharmaceuticals, with a leading Phase II program in Homozygous Familial Hypercholesterolemia...